U.S. Inhalation Anesthesia Market Size & Outlook
U.S. inhalation anesthesia market, 2018-2030 (US$M)
Related Markets
U.S. inhalation anesthesia market highlights
- The U.S. inhalation anesthesia market generated a revenue of USD 572.5 million in 2022 and is expected to reach USD 1,105.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.6% from 2023 to 2030.
- In terms of segment, sevoflurane was the largest revenue generating drug in 2022.
- Isoflurane is the most lucrative drug segment registering the fastest growth during the forecast period.
Inhalation anesthesia market data book summary
| Market revenue in 2022 | USD 572.5 million |
| Market revenue in 2030 | USD 1,105.6 million |
| Growth rate | 8.6% (CAGR from 2022 to 2030) |
| Largest segment | Sevoflurane |
| Fastest growing segment | Isoflurane |
| Historical data | 2016 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sevoflurane, Desflurane, Isoflurane |
| Key market players worldwide | Baxter International Inc, AbbVie Inc, Fresenius SE & Co KGaA, Sandoz Group AG ADR, Piramal Enterprises, Halocarbon Products Corporation, Lunan Pharmaceutical Group |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.2% of the global inhalation anesthesia market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. inhalation anesthesia market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 138.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalation Anesthesia Market Scope
Inhalation Anesthesia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. inhalation anesthesia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalation anesthesia market will help companies and investors design strategic landscapes.
Sevoflurane was the largest segment with a revenue share of 62.41% in 2024. Horizon Databook has segmented the U.S. inhalation anesthesia market based on sevoflurane, desflurane, isoflurane covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. inhalation anesthesia market is experiencing significant growth, primarily driven by the rising prevalence of chronic diseases and an increasing number of surgical procedures. According to the CDC, nearly 6 in 10 adults in the U.S. live with at least one chronic condition.
which necessitates surgical interventions. The American Heart Association estimates that approximately 805,000 Americans suffer a heart attack each year, highlighting the urgent need for effective anesthesia solutions in surgical settings.
Reasons to subscribe to U.S. inhalation anesthesia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. inhalation anesthesia market databook
-
Our clientele includes a mix of inhalation anesthesia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. inhalation anesthesia market , including forecasts for subscribers. This country databook contains high-level insights into U.S. inhalation anesthesia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. inhalation anesthesia market size, by drug, 2018-2030 (US$M)
U.S. Inhalation Anesthesia Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
